Tonix Pharmaceuticals Soars 10.99% on Noble Financial Rating

Mover TrackerMonday, Mar 24, 2025 5:44 am ET

1min read

On March 24, 2025, tonix pharmaceuticals (NASDAQ:TNXP) surged 10.99% in pre-market trading, reflecting a significant upward momentum in investor sentiment.

Tonix Pharmaceuticals recently received an "Outperform" rating from Noble Financial, which contributed to the stock's upward trend. This rating, combined with institutional inflows, has bolstered investor confidence in the company's prospects.

In its latest earnings report for Q4 2024, Tonix Pharmaceuticals reported an EPS of -$9.77, which fell short of analysts' consensus estimates of -$6.23. Despite the miss, the market's reaction suggests that investors are focusing on the company's long-term potential rather than short-term financial performance.

Analysts have set a consensus price target of $585.00 for Tonix Pharmaceuticals, indicating a potential upside of 2,440.17%. This optimistic outlook is driven by the company's strong pipeline and strategic initiatives, which are expected to drive future growth.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.